Spironolactone for heart failure with preserved ejection fraction. - Wikidata - wikimedia - TriplyDB

Spironolactone for heart failure with preserved ejection fraction.

Spironolactone for heart failure with preserved ejection fraction.

http://www.wikidata.org/entity/Q34414462

about

Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives Biomarkers of acute kidney injury and associations with short- and long-term outcomes MicroRNA and Heart Failure Targeting heart failure with preserved ejection fraction: current status and future prospects Impact of Aldosterone Antagonists on Sudden Cardiac Death Prevention in Heart Failure and Post-Myocardial Infarction Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Improved Cardiovascular Disease Outcomes in Older Adults Recent advances in treatment of heart failure Understanding heart failure with preserved ejection fraction: where are we today?What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold?Breakthrough in heart failure with preserved ejection fraction: are we there yet?Review of the top 5 cardiology studies of 2013-14 Reporting trends of randomised controlled trials in heart failure with preserved ejection fraction: a systematic review Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta-Analysis and Systematic Review Heart failure as a general pandemic in Asia Exercise intolerance in heart failure with preserved ejection fraction: more than a heart problem Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies Patient selection in heart failure with preserved ejection fraction clinical trials Is there a new dawn for selective mineralocorticoid receptor antagonism?Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure 'End-stage' heart failure therapy: potential lessons from congenital heart disease: from pulmonary artery banding and interatrial communication to parallel circulation Advances in the management of heart failure: the role of ivabradine Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm What global diastolic function is, what it is not, and how to measure it Diastolic dysfunction Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond Enabling a Learning Health System through a Unified Enterprise Data Warehouse: The Experience of the Northwestern University Clinical and Translational Sciences (NUCATS) Institute Addressing the Heterogeneity of Heart Failure in Future Randomized Trials.Sex differences in cardiovascular disease - Impact on care and outcomes.Global Variations in Patient Populations and Outcomes in Heart Failure Clinical Trials.Evaluation of Short-Term Changes in Serum Creatinine Level as a Meaningful End Point in Randomized Clinical Trials.A 70-year-old woman with heart failure with preserved ejection fraction.Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT.Advances in the pathophysiology and treatment of heart failure with preserved ejection fraction Differential efficacy profile of aldosterone receptor antagonists, depending on the type of chronic heart failure, whether with reduced or preserved left ventricular ejection fraction-results of a meta-analysis of randomized controlled trials Clinical Characteristics and Outcome of Acute Heart Failure in Korea: Results from the Korean Acute Heart Failure Registry (KorAHF).Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials Interatrial shunt devices for heart failure with normal ejection fraction: a technology update.Endothelial mineralocorticoid receptor contributes to systolic dysfunction induced by pressure overload without modulating cardiac hypertrophy or inflammation.

P2860

Q26741152-25033E86-9009-4FED-AC8E-12265C05A864 Q26745219-BA6FD0A5-9D82-4D47-BD6C-489C9FDB50BD Q26750638-8D851861-20A3-470E-8897-7F63495BB873 Q26752956-9709D543-EE35-44A7-925F-EC63B60FCC51 Q26764927-C9FFB00E-0882-496C-A566-FB0960B3D349 Q26766094-B458EDB3-2303-4157-8B78-996CE1A26FEB Q26766223-345FD60C-7FC6-45E8-9E8F-7BD6CDD32663 Q26766590-F4C9582A-6ACF-4F80-B2AD-82F35F590355 Q26771479-4BABFB8E-050D-4DA9-865E-446A534319D9 Q26771999-2922C2A9-2A24-4823-8047-AC6A8D4BDD1A Q26776254-C932A38E-F595-41D4-B934-FEBEC5395536 Q26779538-C895158A-C457-4F81-B4A3-DAFEE263D73E Q26783958-3DA70F96-59BA-4030-B179-FBC0A48C6664 Q26801810-62742360-6163-4C96-BF86-FB601BFF53BD Q26991985-B5BFDFB6-14A6-4CB3-A703-0FFA902586FB Q27000263-5A70011C-5F09-4542-BD37-684316CB48EB Q27015845-09BEF696-BC86-4766-8DC0-F2DF78F3E147 Q27027792-F3291D29-4B42-4782-B8B9-08F72CEFBAE4 Q28066549-79947D06-63F2-403A-898D-81D47924CDAD Q28066921-BE808E20-BD01-439B-9F93-498538430181 Q28072418-0DB5C6AA-58F5-4460-A38E-73C7A94558D3 Q28073079-0D72AE20-5210-4999-9C79-30A48377CF86 Q28077186-F332A165-6383-4D43-94D2-2D53DA27F1D8 Q28087043-D3E8DD2C-52A9-4512-A98F-7FE877C53D46 Q28087715-7EF70C0D-6C4A-4604-A3F9-21706B8498C1 Q28088583-4B387CB4-17F1-4D10-A257-64D0E15C2B81 Q28387104-C7D438FF-E005-4FDC-B889-E9B6EEF83438 Q30234708-B61A6DBD-31F2-482B-A843-297A17A5DE2F Q30234726-F2435961-0383-4783-A968-3A77DCA63312 Q30235985-952927A2-9ADE-4731-906B-9754BC12669B Q30251988-29106A26-CA00-4C81-8B7D-4BAAB49C2C63 Q30359520-92150DF6-3D4F-4DE0-AB41-601765E1276B Q31036336-DC9D55DE-5A89-4667-B91D-600A36BF2955 Q31143932-B545E3F5-FA99-423A-BD46-9BC22B05FC9E Q33565707-8B53A3AE-8733-493E-ABF6-52DC18F7677F Q33714645-3EEC533D-7001-4D43-B1D3-FB879B2973F6 Q33740799-8DECF912-ACE7-48A6-B210-BF35777DAC81 Q33768602-617428FB-D196-4E4C-83FE-68280B19592A Q33812836-8A612CA5-EE86-4F3C-A210-64AB37303BC3 Q33856656-F15CBC64-2DE8-4E66-885A-5ABDE108E4CE

P2860

Spironolactone for heart failure with preserved ejection fraction.

http://www.wikidata.org/entity/Q34414462

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Spironolactone for heart failure with preserved ejection fraction.

@ast

Spironolactone for heart failure with preserved ejection fraction.

@en

Spironolactone for heart failure with preserved ejection fraction.

@nl

type

label

Spironolactone for heart failure with preserved ejection fraction.

@ast

Spironolactone for heart failure with preserved ejection fraction.

@en

Spironolactone for heart failure with preserved ejection fraction.

@nl

prefLabel

Spironolactone for heart failure with preserved ejection fraction.

@ast

Spironolactone for heart failure with preserved ejection fraction.

@en

Spironolactone for heart failure with preserved ejection fraction.

@nl

P1433

Q34414462-B145A041-653F-4A0B-A7D4-A0ED67B6A49C

P1476

Q34414462-F2B9902C-5E51-4139-B876-56041D0EF66B

P2093

Q34414462-0A7F574F-37A4-40D3-AB03-B0C274AA2954

Q34414462-0BA1E5A1-0D8A-4E99-A9CA-27614BA65D53

Q34414462-1ADC4DF2-FC69-48A9-A167-C1DCD5E4B3C7

Q34414462-1B591B1C-5C72-4BFD-97CB-6CBBC53F25D5

Q34414462-219910CB-366C-4A58-BE4A-1BD6A2FE1357

Q34414462-2893CDE0-4C8A-428A-AA9C-9590BF1369C5

Q34414462-3CC14119-C0CA-4DC8-A9DA-8E83FDD0FD34

Q34414462-41931932-F9DA-4BCD-9E6C-6F223CDA436C

Q34414462-43682039-0D23-4358-9784-AE4A61DDF016

Q34414462-48F39415-B472-4209-9FFD-DA6B30F22E61

P304

Q34414462-A4213426-97A2-4099-BD40-BB33ADEA86E2

P31

Q34414462-0E33E781-D868-4534-96AF-57333D1AFD25

P356

Q34414462-1F3F1F3C-3A1C-4E0E-9F9E-CEE874FD3861

P407

Q34414462-803D1726-FC93-45EE-AE35-32AD4762A5E5

P433

Q34414462-D0C6D878-2033-49B2-98A8-F354BA638E3C

P478

Q34414462-95EB0366-E8B8-4EF5-87FA-7964D29EB1F2

P50

Q34414462-C6721E67-BB5F-44FD-A9B9-AEE5D740EBA9

P577

Q34414462-77DC346E-3E51-4C5F-925D-A970FD453412

P698

Q34414462-938A6A32-48A2-4FB2-8984-CD92B3E018AD

P921

Q34414462-86C59204-37BB-48CB-80C3-25BD77B044EF

P356

P1433

The New England Journal of Medicine

P1476

Spironolactone for heart failure with preserved ejection fraction.

@en

P2093

Akshay S Desai

http://www.w3.org/2001/XMLSchema#string

Brian Claggett

http://www.w3.org/2001/XMLSchema#string

Brian Harty

http://www.w3.org/2001/XMLSchema#string

Christopher T Kenwood

http://www.w3.org/2001/XMLSchema#string

Eileen O'Meara

http://www.w3.org/2001/XMLSchema#string

Eldrin F Lewis

http://www.w3.org/2001/XMLSchema#string

Inder S Anand

http://www.w3.org/2001/XMLSchema#string

Ivan Gordeev

http://www.w3.org/2001/XMLSchema#string

Jeffrey L Probstfield

http://www.w3.org/2001/XMLSchema#string

Jerome L Fleg

http://www.w3.org/2001/XMLSchema#string

P304

1383-1392

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1313731

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

370

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24716680

http://www.w3.org/2001/XMLSchema#string

P921